Bullish & Foolish
Full FTH fundamentals All 466 on the Survival Watch

FTHFaeth Therapeutics, Inc.

Is Faeth Therapeutics struggling financially?

Yes, by its own account. Faeth Therapeutics told the SEC on 15 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

30/100

Fragile

Cries for help

  • Mechanism questioned

    Orphan exclusivity operates independently from other regulatory exclusivities and other protection against generic competition, including patents that we hold for our products.

    Form 10-K/A, filed 2 Jun 2026. Read it on SEC.gov

Signs of a way out

Nothing in the filings we have read names a way out.

Sector
Biotech/Pharma
Market cap
$826.9M
Source filing
10-Q 15 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 13months

    If the burn speeds up

    Empty by Jul 2027

  • 19months

    If it eases off

    Empty by Jan 2028

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$26.9M

÷

Cash burned over the last 12 months

$20.5M

What Faeth Therapeutics told the SEC

…reduce the Company’s available cash resources. After evaluating the conditions described above in the aggregate, the Company has concluded that there is substantial doubt about its ability to continue as a going concern. The accompanying consolidated financial statements have been prepared on the basis 5 that the Company will continue to operate as a going concern within the twelve months after the…

Faeth Therapeutics, Inc., Form 10-Q, filed 15 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 176.2% share-count increase The company issued stock. Each share now owns 63.8% less of the business than a year ago, before any change in the price.
  • Cash burn is narrowing It is spending 54% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt